L 767679

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 596696

CAS#: 182198-53-4

Description: L 767679 is a fibrinogen receptor antagonist.


Price and Availability

Size
Price

Size
Price

Size
Price

L 767679 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 596696
Name: L 767679
CAS#: 182198-53-4
Chemical Formula: C20H24N4O4
Exact Mass: 384.1798
Molecular Weight: 384.43
Elemental Analysis: C, 62.49; H, 6.29; N, 14.57; O, 16.65


Synonym: L 767679; L-767679; L767679;

IUPAC/Chemical Name: (S)-3-(2-(1-oxo-7-(piperazin-1-yl)-3,4-dihydroisoquinolin-2(1H)-yl)acetamido)pent-4-ynoic acid

InChi Key: QTVKUFZTCJLGEJ-OAHLLOKOSA-N

InChi Code: InChI=1S/C20H24N4O4/c1-2-15(11-19(26)27)22-18(25)13-24-8-5-14-3-4-16(12-17(14)20(24)28)23-9-6-21-7-10-23/h1,3-4,12,15,21H,5-11,13H2,(H,22,25)(H,26,27)/t15-/m1/s1

SMILES Code: C#C[C@@H](NC(CN(CCC1=C2C=C(N3CCNCC3)C=C1)C2=O)=O)CC(O)=O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Bednar B, Cook JJ, Holahan MA, Cunningham ME, Jumes PA, Bednar RA, Hartman GD, Gould RJ. Fibrinogen receptor antagonist-induced thrombocytopenia in chimpanzee and rhesus monkey associated with preexisting drug-dependent antibodies to platelet glycoprotein IIb/IIIa. Blood. 1999 Jul 15;94(2):587-99. PubMed PMID: 10397726.

2: Prueksaritanont T, DeLuna P, Gorham LM, Ma B, Cohn D, Pang J, Xu X, Leung K, Lin JH. In vitro and in vivo evaluations of intestinal barriers for the zwitterion L-767,679 and its carboxyl ester prodrug L-775,318. Roles of efflux and metabolism. Drug Metab Dispos. 1998 Jun;26(6):520-7. PubMed PMID: 9616186.

3: Prueksaritanont T, Gorham LM, Yeh KC. Analysis of metabolite kinetics by deconvolution and in vivo-in vitro correlations of metabolite formation rates: studies of fibrinogen receptor antagonist ester prodrugs. J Pharm Sci. 1997 Dec;86(12):1345-51. PubMed PMID: 9423143.

4: Prueksaritanont T, Gorham LM, Breslin MJ, Hutchinson JH, Hartman GD, Vyas KP, Baillie TA. In vitro and in vivo evaluations of the metabolism, pharmacokinetics, and bioavailability of ester prodrugs of L-767,679, a potent fibrinogen receptor antagonist: an approach for the selection of a prodrug candidate. Drug Metab Dispos. 1997 Aug;25(8):978-84. PubMed PMID: 9280406.